BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ya K, Tangamornsuksan W, Scholfield CN, Methaneethorn J, Lohitnavy M. Pharmacokinetics of mitragynine, a major analgesic alkaloid in kratom (Mitragyna speciosa): A systematic review. Asian J Psychiatr 2019;43:73-82. [PMID: 31100603 DOI: 10.1016/j.ajp.2019.05.016] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Grundmann O, Hendrickson RG, Greenberg MI. Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits. Dis Mon 2022;:101442. [PMID: 35732553 DOI: 10.1016/j.disamonth.2022.101442] [Reference Citation Analysis]
2 La-up A, Wongrith P, Chaichan W, Aramrattana A, Saengow U. Association between kratom (Mitragyna speciosa) use and metabolic syndrome. Heliyon 2022;8:e09468. [DOI: 10.1016/j.heliyon.2022.e09468] [Reference Citation Analysis]
3 Simão AY, Antunes M, Cabral E, Oliveira P, Rosendo LM, Brinca AT, Alves E, Marques H, Rosado T, Passarinha LA, Andraus M, Barroso M, Gallardo E. An Update on the Implications of New Psychoactive Substances in Public Health. Int J Environ Res Public Health 2022;19:4869. [PMID: 35457736 DOI: 10.3390/ijerph19084869] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Karunakaran T, Ngew KZ, Zailan AAD, Mian Jong VY, Abu Bakar MH. The Chemical and Pharmacological Properties of Mitragynine and Its Diastereomers: An Insight Review. Front Pharmacol 2022;13:805986. [DOI: 10.3389/fphar.2022.805986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Prevete E, Kuypers KPC, Theunissen EL, Corazza O, Bersani G, Ramaekers JG. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. Hum Psychopharmacol 2021;:e2805. [PMID: 34309900 DOI: 10.1002/hup.2805] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Kerrigan S, Basiliere S. Kratom: A systematic review of toxicological issues. WIREs Forensic Science 2022;4. [DOI: 10.1002/wfs2.1420] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 De Neve J, Barlow TMA, Tourwé D, Bihel F, Simonin F, Ballet S. Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. RSC Med Chem 2021;12:828-70. [PMID: 34223156 DOI: 10.1039/d1md00041a] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
8 Prevete E, Hupli A, Marrinan S, Singh D, Udine BD, Bersani G, Kuypers KP, Ramaekers JG, Corazza O. Exploring the use of Kratom (Mitragyna speciosa) via the YouTube data tool: A novel netnographic analysis. Emerging Trends in Drugs, Addictions, and Health 2021;1:100007. [DOI: 10.1016/j.etdah.2021.100007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
9 Ya K MS, Methaneethorn J PhD, Tran QB PhD, Trakulsrichai S MD, Wananukul W MD, Lohitnavy M PhD. Development of a Physiologically Based Pharmacokinetic Model of Mitragynine, Psychoactive Alkaloid in Kratom (Mitragyna Speciosa Korth.), In Rats and Humans. J Psychoactive Drugs 2021;53:127-39. [PMID: 34003732 DOI: 10.1080/02791072.2020.1849877] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Leong Abdullah MFI, Tan KL, Narayanan S, Yuvashnee N, Chear NJY, Singh D, Grundmann O, Henningfield JE. Is kratom (Mitragyna speciosa Korth.) use associated with ECG abnormalities? Electrocardiogram comparisons between regular kratom users and controls. Clin Toxicol (Phila) 2021;59:400-8. [PMID: 32870119 DOI: 10.1080/15563650.2020.1812627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
11 Maxwell EA, King TI, Kamble SH, Raju KSR, Berthold EC, León F, Avery BA, McMahon LR, McCurdy CR, Sharma A. Pharmacokinetics and Safety of Mitragynine in Beagle Dogs. Planta Med 2020;86:1278-85. [PMID: 32693425 DOI: 10.1055/a-1212-5475] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
12 Leong Bin Abdullah MFI, Tan KL, Mohd Isa S, Yusoff NS, Chear NJY, Singh D. Lipid profile of regular kratom (Mitragyna speciosa Korth.) users in the community setting. PLoS One 2020;15:e0234639. [PMID: 32525924 DOI: 10.1371/journal.pone.0234639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
13 Eastlack SC, Cornett EM, Kaye AD. Kratom-Pharmacology, Clinical Implications, and Outlook: A Comprehensive Review.Pain Ther. 2020;9:55-69. [PMID: 31994019 DOI: 10.1007/s40122-020-00151-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
14 Han C, Schmitt J, Gilliland KM. DARK Classics in Chemical Neuroscience: Kratom. ACS Chem Neurosci 2020. [PMID: 31841631 DOI: 10.1021/acschemneuro.9b00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Leong Bin Abdullah MFI, Singh D, Swogger MT, Rahim AA, Vicknasingam B. The prevalence of psychotic symptoms in kratom (Mitragyna speciosa Korth.) Users in Malaysia. Asian J Psychiatr 2019;43:197-201. [PMID: 31302592 DOI: 10.1016/j.ajp.2019.07.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Veltri C, Grundmann O. Current perspectives on the impact of Kratom use. Subst Abuse Rehabil. 2019;10:23-31. [PMID: 31308789 DOI: 10.2147/sar.s164261] [Cited by in Crossref: 38] [Cited by in F6Publishing: 49] [Article Influence: 12.7] [Reference Citation Analysis]